IQVIA and LMC Manna Research to launch Prime Site in Canada

IQVIA has entered a strategic alliance with LMC Manna Research to launch its first Prime Site for clinical investigation in Canada.

LMC Manna Research conducts Phases I-IV studies at 22 trial sites across three provinces. Credit: fernando zhiminaicela from Pixabay.

IQVIA has entered a strategic alliance with LMC Manna Research to launch its first Prime Site for clinical investigation in Canada.

It is the latest addition to the company’s network of over 980 Prime and Partner clinical sites across the world.

These sites with special designation ensure pharmaceutical and biotech companies conduct their clinical trials in premier investigative research centres.

LMC Manna will collaborate with the company on research programmes to optimise processes and minimise the time it takes to start clinical research.

It will also help align procedures and support a significant increase in complex clinical and real-world evidence studies in Canada.

IQVIA Research and Development Solutions president Richard Staub said: “Our partnership with LMC Manna Research leverages a strong infrastructure and transformational technologies to bring research to communities across Canada.”

Content from our partners

The importance of reference products in biosimilar trials, and how to source them

Africa’s last mile: Building viable vaccine supply chains

Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

LMC Manna conducts Phases I-IV studies at 22 trial sites across three provinces in Canada and has access to over 500,000 patients.

As part of the collaboration, IQVIA will offer staff dedicated to LMC Manna. This includes a prime site manager who will be in charge of partnership relations and follow up on the delivery of IQVIA research projects.

LMC Manna Research president Karri Venn said: “We are excited to partner with IQVIA to co-develop strategies to improve clinical research in Canada and globally.

“Our common commitment to bring meaningful research to patients while improving the entire continuum is magnified and made more tangible through this partnership. We look forward to collaborating across multiple domains to bring improvement to clinical research to both Canadians and the industry.”